NASDAQ$APLT
Applied Therapeutics Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2020.
Applied Therapeutics reported its financial results for the second quarter ended June 30, 2020, while continuing to advance its late-stage programs towards regulatory submission and commercial launch.
- Advanced late-stage programs towards regulatory submission.
- Focused on bringing drugs to patients in urgent need of treatment.
- Pivotal Phase 1/2 clinical trial in Galactosemia read out positive top-line biomarker data.
- Phase 3 registrational study in DbCM was initiated in September 2019.
Headline financials
Revenue & EPS history
Applied Therapeutics · Revenue · Quarterly
$1M
Forward guidance
The company remains focused on bringing drugs to patients in urgent need of treatment across multiple diseases, which they believe will ultimately drive shareholder value.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports
-2.6%
Avg return
Earnings day
-9.9%
Avg return
5 days after
-14.9%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+24.0%
Q1 2025
Best reaction
-71.6%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -71.6% | -68.9% | -77.9% | |
| Q2 2025 | +5.6% | +9.1% | -5.6% | |
| Q1 2025 | +24.0% | -22.5% | -26.9% | |
| Q4 2024 | +0.1% | +4.3% | +1.5% | |
| Q3 2024 | +4.6% | +2.7% | -86.8% | |
| Q2 2024 | +5.7% | -4.4% | -6.4% | |
| Q1 2024 | -6.8% | -1.9% | -1.3% | |
| Q4 2023 | +7.3% | +2.6% | -6.2% | |
| Q3 2023 | -12.1% | -10.8% | +34.6% | |
| Q2 2023 | -3.2% | -14.1% | +1.3% | |
| Q1 2023 | -3.6% | -7.3% | -10.9% | |
| Q4 2022 | -5.6% | -7.9% | +6.3% | |
| Q3 2022 | -0.2% | — | — | |
| Q2 2022 | +3.0% | — | — | |
| Q1 2022 | -1.7% | — | — | |
| Q4 2021 | -9.1% | — | — | |
| Q3 2021 | +1.6% | — | — | |
| Q2 2021 | +3.6% | — | — | |
| Q1 2021 | -2.2% | — | — | |
| Q4 2020 | +3.3% | — | — | |
| Q3 2020 | +5.9% | — | — | |
| Q2 2020 | +13.8% | — | — | |
| Q1 2020 | +3.3% | — | — | |
| Q4 2019 | -27.7% | — | — | |
| Q3 2019 | -7.5% | — | — | |
| Q2 2019 | +7.0% | — | — | |
| Q1 2019 | -6.7% | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro